779-P: Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a U.S. EHR and Claims Linked Database

Introduction one year (T2DM: 29%, CWM: 13%). Conclusion: Real-world patients using GLP-1RAs for T2DM and CWM have comparable BMI despite differences in age, sex, and clinical characteristics. Duration of GLP-1RA use is short in clinical practice. Disclosure M.S. Girguis: Employee; Amgen Inc. M. Lillie: Employee; Amgen Inc. E. Bodner: None. C.K. Kasrai: None. J.R. Spencer: None. A. Cancino Nunez: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. Employee; Amgen Inc. Stock/Shareholder; Amgen Inc. J. O'Kelly: Employee; Amgen Inc. Stock/Shareholder; Amgen Inc.